Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 May 2017 07:00

RNS Number : 6026F
Scancell Holdings Plc
19 May 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Scancell Holdings PLC

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc

Legal & General (Unit Trust Managers) Limited (UTM)

Legal & General Investment Management Limited (LGIM)

4. Full name of shareholder(s)  (if different from 3.):

n/a

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

16 May 2017

6. Date on which issuer notified:

18 May 2017

7. Threshold(s) that is/are crossed orreached:

 

 

 

LGIM (Above 5%) UTM (Above 5%)

 

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP0.001

 

(LGIM)

 

First notification under DTR Sourcebook

 

 16,000,000

-

16,000,000

-

5.13%

ORD GBP0.001

 

(UTM)

 

First notification under DTR Sourcebook

16,000,000

-

16,000,000

-

5.13%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 16,000,000

 

LGIM

 

5.13%

 

 16,000,000

 

UTM

 

5.13%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 16,000,000 -5.13% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 16,000,000 - 5.13% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 16,000,000 - 5.13% = Total Position)

Legal & General (Unit Trust Managers) Limited ( 16,000,000 - 5.13% = UTM)

Legal & General Group Plc (Direct) (L&G)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance (Pensions Management) Limited (PMC)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  312,058,098

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFREVITLID
Date   Source Headline
18th Jan 20237:00 amRNSNotice of Interim Results
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20223:18 pmRNSResult of Annual General Meeting
7th Nov 20227:00 amRNSLicenses Vaccitech technology to advance Modi-2
31st Oct 20227:00 amRNSFirst patient dosed in expansion phase of ModiFY
28th Oct 20223:00 pmRNSNotice of AGM
28th Oct 20227:00 amRNSResults for the year ended 30 April 2022
26th Oct 20227:00 amRNSDirectorate Changes
25th Oct 20224:42 pmRNSSecond Price Monitoring Extn
25th Oct 20224:37 pmRNSPrice Monitoring Extension
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 202211:05 amRNSSecond Price Monitoring Extn
25th Oct 202211:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSSigns Commercial License Agreement with Genmab
13th Oct 20227:00 amRNSChange of Nominated Adviser
28th Sep 202212:31 pmRNSHolding(s) in Company
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
6th Sep 202212:54 pmRNSChange of Registered Office
16th Aug 20222:00 pmRNSFirst patient dosed in Cohort 2 of the ModiFY
23rd Jun 20227:00 amRNSScancell to produce TCB antibodies
15th Jun 20222:06 pmRNSSecond Price Monitoring Extn
15th Jun 20222:00 pmRNSPrice Monitoring Extension
15th Jun 20227:00 amRNSPhase 2 SCOPE trial of SCIB1 vaccine expanded
13th Jun 20227:00 amRNSFirst patient dosed in Modi-1 Phase 1 trial
12th Apr 20223:47 pmRNSChange of Registered Holder of Shares
11th Apr 20222:06 pmRNSSecond Price Monitoring Extn
11th Apr 20222:00 pmRNSPrice Monitoring Extension
11th Apr 202211:05 amRNSSecond Price Monitoring Extn
11th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSModi-1 Phase 1/2 trial open for recruitment
29th Mar 20227:00 amRNSUpdate on COVIDITY clinical trial
17th Mar 20227:00 amRNSScancell progresses its new anti-glycan mAb
3rd Mar 20229:55 amRNSDirector Dealing
31st Jan 20227:00 amRNSUpdate on COVIDITY Phase 1 clinical trial
26th Jan 20227:00 amRNSInterim Results for the 6 months ended 31 Oct 2021
22nd Dec 20219:45 amRNSNotice of Interim Results
13th Dec 20214:41 pmRNSSecond Price Monitoring Extn
13th Dec 20214:36 pmRNSPrice Monitoring Extension
23rd Nov 20213:58 pmRNSResult of AGM
19th Nov 20217:00 amRNSFirst patient dosed in SCIB1 Phase 2 trial
3rd Nov 202110:28 amRNSDirector Dealing
2nd Nov 202110:07 amRNSDirector Dealing
1st Nov 20219:50 amRNSNotice of Annual General Meeting
29th Oct 20217:00 amRNSResults for the year ended 30 April 2021
28th Oct 202111:23 amRNSExtension of CLN Redemption Dates
19th Oct 20217:00 amRNSNew facilities at The Oxford Science Park
15th Oct 20217:00 amRNSNotice of Final Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.